AstraZeneca PLC (AZN)vsOrganogenesis Holdings Inc (ORGO)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
ORGO
Organogenesis Holdings Inc
$2.35
+2.17%
HEALTHCARE · Cap: $307.45M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 10312% more annual revenue ($58.74B vs $564.17M). AZN leads profitability with a 17.4% profit margin vs 6.6%. ORGO trades at a lower P/E of 15.9x. ORGO earns a higher WallStSmart Score of 67/100 (B-).
AZN
Buy64
out of 100
Grade: C+
ORGO
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+80.1%
Fair Value
$18.81
Current Price
$2.35
$16.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Earnings expanding 555.0% YoY
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 78.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while ORGO is a hypergrowth play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.48 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
ORGO scores higher overall (67/100 vs 64/100) and 78.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?